Apexigen is a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. The company’s pipeline of immuno-oncology therapeutic candidates is led by sotigalimab, which is currently in clinical development, and also includes several preclinical stage immune-oncology programs.

Apexigen’s APXiMAB™ technology platform enables Apexigen and its partners to discover high-quality antibody drug candidates against challenging disease targets. Apexigen has established multiple corporate partnerships: five of these partners are conducting clinical trials of antibodies discovered through the use of the APXiMAB™ platform.

Management Team

Board of Directors

Scientific Advisors